Antimycobacterial assessment of Salicylanilide benzoates including multidrug-resistant tuberculosis strains

Molecules. 2012 Oct 31;17(11):12812-20. doi: 10.3390/molecules171112812.

Abstract

The increasing emergence especially of drug-resistant tuberculosis has led to a strong demand for new anti-tuberculosis drugs. Eighteen salicylanilide benzoates were evaluated for their inhibition potential against Mycobacterium tuberculosis, Mycobacterium avium and two strains of Mycobacterium kansasii; minimum inhibitory concentration values ranged from 0.5 to 16 μmol/L. The most active esters underwent additional biological assays. Four benzoates inhibited effectively the growth of five multidrug-resistant strains and one extensively drug-resistant strain of M. tuberculosis at low concentrations (0.25–2 μmol/L) regardless of the resistance patterns. The highest rate of multidrug-resistant mycobacteria inhibition expressed 4-chloro-2-[4-(trifluoromethyl)-phenylcarbamoyl]phenyl benzoate (0.25–1 μmol/L). Unfortunately, the most potent esters were still considerably cytotoxic, although mostly less than their parent salicylanilides.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Antitubercular Agents / toxicity
  • Benzoates / pharmacology*
  • Benzoates / toxicity
  • Cell Survival / drug effects
  • Drug Resistance, Multiple, Bacterial
  • Hep G2 Cells
  • Humans
  • Inhibitory Concentration 50
  • Microbial Sensitivity Tests
  • Mycobacterium avium / drug effects
  • Mycobacterium kansasii / drug effects
  • Mycobacterium tuberculosis / drug effects*
  • Salicylanilides / pharmacology*
  • Salicylanilides / toxicity

Substances

  • Antitubercular Agents
  • Benzoates
  • Salicylanilides